■ Researchers led by Anthony T. Scott, MHI, of the University of Colorado School of Medicine, set out to determine whether iCare Home tonometry could provide more accurate and complete monitoring of therapy-related IOP changes than reliance on office visits alone.

A total of 43 eyes with open-angle glaucoma or ocular hypertension were grouped into control eyes managed on stable therapy (n=18 eyes) or therapy-change eyes undergoing SLT (n=8 eyes), initiating topical therapy (n=8 eyes), or adding a second medication to existing monotherapy (n=9 eyes). Subjects recorded IOP 4 times daily for 1 week using iCare Home tonometry. Upon tonometer return, subjects underwent SLT or new medication start; an additional week of iCare Home measurements was collected after 4 to 6 weeks. Control subjects recorded an additional week of measurements after 6 weeks. Goldmann applanation tonometry (GAT) was performed at each study visit for comparison.

For eyes that demonstrated a therapy response by GAT (n=11), iCare Home detected a therapy response in 90.9% of eyes at ≥1 time point and 45.5% of eyes in all 4 time points. In eyes without a GAT-measured therapy response (n=14), iCare Home detected a response for 71.4% (n=10) of eyes at ≥1 time point and for 7.1% of eyes (n=1) at all 4 time points.

The researchers, who reported their findings in Ophthalmology Glaucoma, concluded that iCare Home reliably detects therapy-related IOP changes in patients with glaucoma and ocular hypertension. Treatment responses correlated well with in-office GAT and may detect treatment responses missed by GAT. Intraocular pressure measurements via home tonometry provide additional clinical information regarding intraday and interday IOP fluctuation beyond standard of care in-office GAT measurements.